News

Phillips Edison & Company Reports Strong Growth for 2025

Phillips Edison & Company Reports Strong Growth for 2025

Phillips Edison & Company Announces Positive Financial Results

Phillips Edison & Company, Inc. (NASDAQ: PECO) has reported impressive financial results for the recent quarter, reflecting their strong operational performance in managing grocery-anchored neighborhood shopping centers. The company has showcased resilience and growth during the period, resulting in increased earnings guidance for the remainder of the year.

Quarterly Highlights

For the third quarter of the year, the company reported net income attributable to shareholders of $24.7 million, equivalent to $0.20 per diluted share. This represents a significant rise compared to the same period last year, highlighting the company's robust financial health.

Key financial performance indicators include:

  • Reported Nareit Funds from Operations (FFO) increased to $89.3 million, translating to $0.64 per diluted share.
  • Core FFO soared to $90.6 million, or $0.65 per diluted share.
  • Year-over-year growth in Nareit FFO reflects a solid 9.4% increase.
  • Core FFO also saw a growth of 7.3% compared to the previous year.
  • The company successfully maintained a total portfolio occupancy of 97.6%.
  • Leasing activity remained strong with a record-high rent spread of 23.2% on comparable renewal leases.

Innovative Management Approach

Jeff Edison, the Chairman and CEO, emphasized the company's solid earnings growth and the strong demand for grocery-anchored centers. He noted that the operational results showcase the effectiveness of their management strategies and the appeal of maintaining robust occupancy levels.

Overall Performance Metrics

The results indicate an adaptive and strategic management decision-making process, with the company executing 270 leases also comprising approximately 1.7 million square feet within the third quarter. Comparing the execution of 268 leases in the same quarter last year showcases their operational excellence and capacity for growth.

Portfolio Overview

As of the end of the reporting period, Phillips Edison & Company’s portfolio comprised 303 properties totaling around 34 million square feet spread across 31 states. This expansion from 290 properties a year prior signals a robust growth strategy fueled by strategic investments and acquisitions.

In line with its growth objectives, the company acquired assets worth $21.9 million, including shopping centers and land parcels, and has diversified its holdings to ensure sustained occupancy and rental income. The ongoing acquisition strategy is well-supported by the guidance indicating gross acquisitions ranging from $350 million to $450 million.

Future Prospects and Guidance

Looking ahead, Phillips Edison & Company has adjusted its earnings guidance, reflecting its positive outlook based on the current market conditions and operational performance. The company has projected Nareit FFO per share for the full year in the range of $2.51 to $2.55, and core FFO in the range of $2.57 to $2.61.

This guidance adjustment reflects the company's confidence in its sustained operational execution and the favorable market conditions supportive of continued growth.

Investor Relations and Support

For further inquiries, stakeholders can reach out to the Investor Relations team. The company is committed to maintaining transparent communication with its investors to keep them informed about the ongoing strategies and performance metrics.

Frequently Asked Questions

What are the recent financial highlights for Phillips Edison & Company?

The recent report highlighted a sharp increase in net income to $24.7 million and significant growth in Nareit FFO and Core FFO by 9.4% and 7.3%, respectively.

How does the company's portfolio perform?

The total portfolio occupancy stood strong at 97.6%, indicating effective management and high demand for grocery-anchored shopping centers.

What strategic acquisitions has Phillips Edison & Company made?

The company reported acquiring assets worth $21.9 million recently, contributing to its expanding portfolio of shopping centers and land.

What growth projections has the company set for the remaining year?

Phillips Edison & Company has updated its guidance to reflect a projected range for Nareit FFO per share of $2.51 to $2.55.

Who can I contact for investor relations inquiries?

Investors can reach out to Kimberly Green, Head of Investor Relations, or Hannah Harper, Senior Manager of Investor Relations, for further assistance.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

Gildan's Crisis: Investors Face Losses Amid Lawsuit

Updated Category News Views 245

Gildan Investors, Brace Yourself Poor old Gildan Activewear finds itself in hot water again, with a class action lawsuit cropping up like an unexpected storm on farmers' day. Any traders remotely involved with NYSE:GIL should pay damn close attention, because with a December 14, 2026 deadline looming, it's crunch time. The Root of the Lawsuit The plot thickens here,...

Continue Reading
D-Wave's Legal Trouble: Securities Fraud Suit Looms

Updated Category News Views 308

A Looming Legal Storm for D-Wave Investors Call it another day, another legal tangle in the investing world. This time, it's D-Wave Quantum Inc. (NASDAQ: QBTS) on the receiving end of a securities fraud class action lawsuit. Yeah, those fancy quantum computers they're pushing didn't predict this one coming. The legal arena is getting ready for a bout, and if you've got...

Continue Reading
Novo's Semaglutide Shows Promise in MASH Study

Updated Category News Views 337

Semaglutide, a name on the lips of many investors looking for breakthroughs, is making waves again. This time, the stir comes from recent findings in the MASH field, and it's got folks in white coats quite excited. Revolutionary Results from Novo Novo Nordisk has announced promising results from their phase 3 ESSENCE trial that looks into semaglutide's effects on a...

Continue Reading
GlycoNex Eyes Japanese Market with Denosumab Biosimilar

Updated Category News Views 9

A Strategic Step into the Japanese Market Alright folks, there's a new kid aiming to shake things up in the biotech neighborhood, and it's GlycoNex with its denosumab biosimilar, SPD8. These guys just tossed their hat in the ring with a regulatory submission to Japan's Pharmaceuticals and Medical Devices Agency (PMDA). If the cosmic forces align, they might snag an...

Continue Reading
Antengene’s AnTenGager-D2 Advances in Cancer Treatment

Updated Category News Views 26

Antengene's AnTenGager-D2 Offers Fresh Hope Alright, let's dig into the latest buzz from the 2026 Society for Immunotherapy of Cancer conference about Antengene's AnTenGager-D2 platform. If you're not into biotech lingo, buckle up, because this is a ride into the future of cancer treatments—where science fiction might soon become science fact. A Novel Approach to Tumor...

Continue Reading
Fibocom LTE Modules Test Drive Satellite Connectivity

Updated Category News Views 153

Boosting IoT with Satellite Connectivity Here's a good one for folks watching the edge of wireless innovation. Fibocom's LTE Cat.1 bis modules, the LE270-EU and LE271-GL, just stretched their legs in New Zealand, connecting seamlessly with SpaceX's Direct to Cell (DTC) satellite system. No fancy hardware swaps, just standard firmware strutting its stuff across satellite...

Continue Reading
Allergan Aesthetics Study Shows Rising Patient Satisfaction

Updated Category News Views 344

Enhanced Patient Satisfaction with Aesthetic Treatments Dive into the latest studies from Allergan Aesthetics—AbbVie's heavyweight in the beauty battleground. If you've got an ounce of optimism left in this market, their recent findings might just lift your spirits. Phase 4 studies, namely HARMONY IN DIVERSITY and HALO, are showing highly positive results among patients...

Continue Reading
JNJ's Dual-Antigen Therapy Shows Promise in Prostate Cancer

Updated Category News Views 273

Exploring a New Front in Cancer Treatment Johnson & Johnson (NYSE: JNJ) just dropped a bombshell at the Society for Immunotherapy of Cancer (SITC) 2026 Annual Meeting, unveiling data that could reshape prostate cancer care. Their pioneering combo of pasritamig and JNJ-9401, a dual-antigen-targeted therapy, has the scientific community buzzing. Yeah, it's just Phase 1 baby...

Continue Reading
Innovent's SINTBILO® Hits Primary Endpoint in Study

Updated Category News Views 78

Innovent's Latest Breakthrough with SINTBILO® One moment you're sipping coffee, the next you're staring at a clinical milestone. Innovent Biologics has shouted from the rooftops that their drug, SINTBILO® (tafolecimab injection), has wrapped up its Phase 3 CREDIT-5 study, snagging the primary endpoint with both hands. This isn't just any drug; it's marked as the first...

Continue Reading
Cleaner Air in Bedroom May Stabilize Blood Sugar Levels

Updated Category News Views 321

Imagine a world where simply sleeping in cleaner air could affect your blood sugar. Seems far-fetched, I know. But that's where we're at with this new study out of NYU Langone Health. They're talking about using plain ol' portable air filters to help steady blood sugar levels for folks dealing with prediabetes. Turns out a cleaner bedroom might just hold the key to taming...

Continue Reading

Top 5 Most Recently Viewed Articles

BioSyent Inc. to Announce Q3 Financial Results This Month

Updated Category News Views 189

BioSyent Inc. to Announce Q3 Financial Results BioSyent Inc., a prominent player in the specialty pharmaceutical industry, is preparing to release its financial results for the third quarter and year-to-date period. This important announcement is scheduled for November 20, prior to the market opening. The report will cover the company's performance for the three and nine...

Continue Reading
Dr. Ryan Egeland Joins Solventum as Chief Medical Officer

Updated Category News Views 381

Solventum Welcomes Dr. Ryan Egeland as New CMO Solventum, a pioneering healthcare company, recently announced the appointment of Dr. Ryan Egeland, MD, as their Chief Medical Officer. In this significant role, Dr. Egeland will lead the Global Medical and Clinical Affairs team, amplifying clinician and patient voices within the organization. Fostering Collaboration and...

Continue Reading
MiningToken Revolutionizes Cryptocurrency With AI Power

Updated Category News Views 186

Introducing MiningToken's Innovative AI Cloud Mining Service Bitcoin and Ethereum are experiencing remarkable market dynamics as Bitcoin persists in a bullish trend and Ethereum has gained notable ground recently. As global interest in cryptocurrencies grows, effective mining strategies are crucial for profitability. Amidst rising operational costs, many individuals seek...

Continue Reading
Saluda Medical's EVA™ Sensing Technology Approved in Europe

Updated Category News Views 111

Saluda Medical Achieves Regulatory Milestone with EVA™ Technology Saluda Medical, Inc. (ASX:SLD) has made significant strides in the medical device industry by achieving CE certification for its next-generation EVA™ Sensing Technology. This advancement not only marks a major endorsement in Europe but also is recognized in Australia. Following FDA approval in December...

Continue Reading
ReadPartner Inc. Unveils Revolutionary AI Tool to Combat Misinformation

Updated Category News Views 291

ReadPartner Inc. Launches AI Feature to Tackle Misinformation ReadPartner Inc., a leader in AI-driven media intelligence solutions, is excited to announce the upcoming launch of a groundbreaking digital security feature named ProfileScreen. This innovative tool aims to address the pressing issue of misinformation that plagues social media platforms. The ProfileScreen...

Continue Reading